Skip to content

Efficacy of Heated Humidified High-Flow Nasal Cannula (HHHFNC) Driven Nebulization

A Randomized Controlled Trial on the Efficacy of Heated Humidified High-Flow Nasal Cannula (HHHFNC) Driven Nebulization vs. Conventional Nebulization in children with Bronchiolitis - nil

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/02/080366
Enrollment
62
Registered
2025-02-12
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J211- Acute bronchiolitis due to human metapneumovirus Health Condition 2: J218- Acute bronchiolitis due to other specified organisms Health Condition 3: J210- Acute bronchiolitis due to respiratory syncytial virus Health Condition 4: J219- Acute bronchiolitis, unspecified

Interventions

Intervention1: Heated Humidified High Flow Nasal Cannula (HHHFNC) driven nebulization: HFNC-driven nebulization using jet nebuliser (connected to the HFNC through a T channel) with recommended aerosol

Sponsors

Manikandan Arunasalam Kasi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Infants and young children aged 0-2 years with bronchiolitis diagnosed clinically by physician supported by X-ray and laboratory investigations will be included.

Exclusion criteria

Exclusion criteria: Any patients requiring immediate respiratory support (non-invasive or invasive mechanical ventilation), altered mental status, or apnoea at presentation), those already admitted to the ICU due to respiratory failure, those with underlying chronic lung disease or cardiovascular disorders, those with obstructions of the upper respiratory tract, and those with cranial malformations will be excluded.

Design outcomes

Primary

MeasureTime frame
Change in respiratory distress scores from baseline. (Downes score) Timepoint: Duration of study : 12 to 18 months No specified frequency, continued throughout the course of the individual treatment.

Secondary

MeasureTime frame
Need for Escalation of respiratory support. Timepoint: 12 to 18 months;Duration of hospital stay. Timepoint: 12 to 18 months;Adverse events related to the nebulization technique.Timepoint: 12 to 18 months

Countries

India

Contacts

Public ContactDr Alexander

Department of Paediatrics, Chettinad Hospital and Research Institute

paedsalex@gmail.com9551607900

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026